Your Article Summary
Sirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/17/06
Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced that it has completed a merger with Sytera, Inc., a biopharmaceutical firm based in La Jolla, California committed to discovering new treatments for dry AMD (age- related macular degeneration). The announcement was made jointly by Sirion President and CEO Barry Butler, and Sytera Chairman and CEO Kenneth J. Widder, M.D. The financial terms were not disclosed
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur and the Alliance for Rabies Control enter into a global partnership
Sanofi-aventis, 10/05/09
Sanofi-aventis to acquire Oenobiol, French leader in nutritional beauty supplements
Sanofi-aventis, 11/02/09
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
GlaxoSmithKline, 10/14/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Article Search
Sponsor


See Latest Articles


